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Plant possess myriads of secondary metabolites with a broad spectrum of health-promoting 39 benefits. Plant-derived natural products (PNPs) have been used to suppress tumor growth, 40 inhibit retrovirus replication, treat metabolic disease and modulate cholesterol level in both 41 animal and human tests 1 . Up to date, plant extraction is still the primary route to produce PNPs 42 1 . However, isolation of PNPs from their native sources is limited by low abundance and 43 environmental, seasonal, and regional variations. Total chemical synthesis of complex PNPs 44 often involves toxic catalyst and is commercially unsustainable due to low yield, safety concerns 45 and strict GMP regulations 2 . Genome-mining of plant metabolic pathways 3-8 and reconstruction 46 of biosynthetic gene clusters (BGCs) in industrially-relevant microbes offer significant promise 47 for discovery and scalable synthesis of plant natural products. 48 E. coli and S. cerevisiae have long been established as host strains to manufacture a large 49 variety of plant natural products 3, 7-14 . The recent development of oleaginous yeast platforms 50 offers significant advantages over E. coli and S. cerevisiae (Table 1 ). The high precursor 51 acetyl-CoA and malonyl-CoA flux along with the hydrophobic lipid bodies make oleaginous 52 yeast a promising host to produce various natural products with complex structures. For example, 53 Y. lipolytica is known to internalize substantial portion of carbon feedstock as lipids and fatty 54 acids 15, 16 , which provides the ideal amphiphilic environment for the catalytic function of many 55 plant-derived enzymes. It has been recognized as a 'generally regarded as safe' (GRAS) 56 organism for the production of organic acids, polyunsaturated fatty acids (PUFAs) 17, 18 and 57 carotenoids [19] [20] [21] [22] in the food and nutraceutical industry. Compared to S. cerevisiae, Y. lipolytica 58 lacks Crabtree effects, which doesn't require the co-feeding of ethanol for cell to grow. Flavonoids represent a diversified family of phenylpropanoid-derived plant secondary 66 metabolites, with an estimated 10,000 unique structures 41, 42 . They are widely found in fruits, 67 vegetables and medicinal herbs and plants. Pharmaceutical studies and animal tests have 68 demonstrated their anti-obesity, anti-cancer, anti-inflammatory, and anti-diabetic activities 43, 44 . 69
Flavonoids are among the phytochemicals with proven activity towards the prevention of 70 aging-related diseases, including the treatment of nervous and cardiovascular diseases, 71
Parkinson's and Alzheimer's disease etc. 45 . These health-promoting benefits make flavonoids a 72 distinct family of molecules to fight aging in personal care, nutraceutical industry and clinical 73 trials. Considering the worldwide population with age older than 65 will triple in next 30 years 74 (data from WHO, world health organization), there will be increasing interests and sustainable 75 market demand globally in the near future. 76
To prepare the technological ground and enable microbial synthesis, various flavonoid 77 pathways have been reconstituted in various microbial species including E. coli and S. cerevisiae 78 recently, and the recombinant production of an array of molecules such as naringenin 46 Further expression of the plant-derived P450 enzymes, including the flavanol-3' hydroxylase 110 (GhF3'H) from Gerbera hybrid led the engineered strain to produce about 110.5 mg/L of 111 taxifolin and 134.2 mg/L of eriodictyol. This work set the foundation for us to engineer 112 oleaginous yeast as chassis for cost-efficient production of flavonoids and hydroxylated 113 flavonoids. The functional expression of plant-derived polyketide synthase, P450 114 monooxygenase and reductases will expand our capability to access nature's biosynthetic 115 potential for drug discovery and natural product manufacturing. 116
Results and discussion The availability of intracellular malonyl-CoA was reported to be a rate-limiting step of 119 flavonoid synthesis in many microorganisms [69] [70] [71] . Considering the high acetyl-CoA and 120 malonyl-CoA flux, we firstly reconstructed the synthetic pathway and validated the feasibility of 121 using Y. lipolytica as the chassis to produce flavonoids. In addition, the cytochrome c P450 122 (CYP) flavonoid 3'-hydroxylase (F3'H) plays a critical role in oxidizing the phenyl ring and 123 generating hydroxylated flavonoids 72 . Based on the distribution of potential rate-limiting steps, 124
we rationalized and partitioned the flavonoids pathway into two modules, the naringenin 125 synthesis module (Module I) and the hydroxylation module (Module II) (Fig. 1) We observed that all eight constructs containing 4CL, CHS and CHI resulted in the synthesis of 137 naringenin from p-coumaric acid, with production ranging from 10 mg/L to 21.5 mg/L (Fig. 3a) . 138
Interestingly, the three top producers (Fig. 3a) share the same source of chalcone synthase from 139 Petunia x hybrid, indicating that chalcone synthase dictates the efficiency of Module I. To 140 achieve de novo synthesis of naringenin, we further introduced tyrosine ammonia-lyase (RtTAL) 141 from Rhodotorula toruloides, which has been reported to generate phenylpropanoid precursors 142 from glucose 47, 73 . With the overexpression of RtTAL, we detected p-coumaric acid as the direct 143
de-amination product of tyrosine ( Supplementary Fig. S1 ). By complementing the 144 4CL-CHS-CHI pathway, the resulted strain Y. lipolytica Po1f/T4SI produced 14.9 mg/L 145 naringenin from glucose ( Supplementary Fig. S1 ). Increasing the copy number of SlF3H and GhF3'H did not have obvious effect on eriodictyol or 197 taxifolin production (Fig. 4b) , indicating that CPR is the rate-limiting step in Module II. 198
Eriodictyol and taxifolin titers remained stable, when the gene copy number for CrCPR was 199 increased from 2 to 5, suggesting that the optimal ratio of F3'H to its reductase CrCPR is 1:2, 200 which is consistent with previous report 86 . The naringenin-to-eriodictyol and taxifolin 201 conversion ratio reached 90.5% and 56.8%, respectively (Fig. 4b) biotin-apoprotein ligases were introduced to the naringenin-producing strain. All three ACCs 240 could lead to substantial improvement in naringenin production (Fig. 5a) , with YlACC1 241 demonstrating most obvious effect. For example, overexpression of YlACC1 in Po1f/AT4Sx5I 242 improved naringenin titer by 61.4%, reaching 131.7 mg/L (Fig. 5a ). The coupling of 243
Ec_accABCD with EcBirA also resulted in naringenin production increasing by 22% compared 244 with the strain without EcBirA overexpression, indicating the essential role of biotinylation in 245 bacterial ACC activity. This is the first report that EcACC could be functionally expressed in 246 oleaginous species. Unlike the bacterial ACC, co-expression of YlACC1 and YlBPL1 resulted in 247 decreased naringenin production (Fig. 5a ). Boosting flavonoid production by bioprocess optimization 270
The C/N ratio is an important factor for regulating the acetyl-CoA and NADPH fluxes in 271
Yarrowia lipolytica 33 . It has been reported that nitrogen starvation triggers the repression of 272 TCA cycle and induces lipogenesis in oleaginous species 96, 97 . It was recently discovered that 273 C/N ratio dynamically regulates lipogenic promoter activity in Y. lipolytica 33 . In this study, C/N 274 ratio was optimized in two patterns to improve flavonoid synthesis, by either adjusting the 275 amount of nitrogen source (ammonia sulfate) or carbon source (glucose). The results showed 276 that altering (NH4)2SO4 content did not have obvious effect on naringenin titer. Slightly higher 277 naringenin titer was achieved at higher C/N ratio (C/N=120) (Supplementary Fig. S2a ). On the 278 contrary, it was clearly shown that higher C/N ratio was advantageous to improving naringenin 279 titer by increasing the level of glucose. Specifically, naringenin titer was increased about 56% 280 when the C/N was altered from 40 to 160 ( Supplementary Fig. S2b) Supplementary Fig. S4 ). We also analyzed the combinatory effects of inhibiting fatty 293 acid synthesis by adding cerulenin 99 , maintaining stable pH, and supplying sodium acetate. The 294 fermentation time course showed that we could achieve steady improvement in naringenin 295 production ( Supplementary Fig. S5 ). For example, supplementation of 1 mg/L cerulenin with 40 296 g/L CaCO3 further improved naringenin titer by 31.2%, (Supplementary Fig. S5c ). However, 297 supplying 5 mM NaAc did not result in further increase in naringenin production 298 ( Supplementary Fig. S5d ). By intermittently feeding glucose after 48 hours, the 299 chromosomally-integrated strain produced 252.4 mg/L naringenin under optimal conditions (Fig.  300  6a ). Likewise, we tested the eriodictyol and taxifolin production in YPD medium by buffering 301 media pH with 40 g/L CaCO3 and inhibiting fatty acid synthesis with 1 mg/L cerulenin. We 302 observed that strains ErioPro and TaxiPro produced 95.5 mg/L eriodictyol and 79.1 mg/L 303 taxifolin in 144 h, which were 76.2% and 64.4% higher than that without CaCO3 and cerulenin. 304
ErioPro and TaxiPro produced 134.2 mg/L eriodictyol and 110.5 mg/L taxifolin at the end of the 305 fermentation process (Fig. 6b) To achieve de novo synthesis of eriodictyol and taxifolin, we transformed 357 pYLXP'2-GhF3'H-CrCPR and pYLXP'2-GhF3'H-CrCPR-SlF3H into Po1f/T4SI, resulting in 358
Po1f/T4SIHR and Po1f/T4SIHRH, respectively. The strain containing 5 copies of PhCHS was 359 named as Po1f/T4Sx5I. We chose to use the plasmids pYLXP'2-HRx2 and pYLXP'2-HRx2H, 360 which contain 2 copies of CrCPR, to construct eriodictyol and taxifolin pathways. To achieve de 361 novo synthesis of eriodictyol and taxifolin, strains Po1f/T4Sx5IHRx2 and Po1f/T4Sx5IHRx2H 362 were constructed by transforming plasmids pYLXP'2-HRx2 and pYLXP'2-HRx2H into strain 363
Po1f/T4Sx5I, respectively. We over-expressed YlARO1 along with YlACS2-YlACC1 in strain 364
Po1f/T4Sx5I, and name the new strain as Po1f/AT4Sx5I-YlACS2-YlACC1. By introducing 365
Module II into strains Po1f/AT4Sx5I and Po1f/AT4Sx5I-YlACS2-YlACC1, we obtained 366 eriodictyol producing strains Po1f/AT4Sx5IHRx2 and Po1f/AT4Sx5IHRx2-YlACS2-YlACC1 and 367 taxifolin producing strains Po1f/AT4Sx5IHRx2H and Po1f/AT4Sx5IHRx2H-YlACS2-YlACC1. 368
Strains constructed in this project were listed in Supplementary Table S2 . 369
Pathway construction 370
Genes RtTAL, Pc4CL, PhCHS, MsCHI, EcACS, CgACC, YlCPR, YlACS2, ScCPR1, and 371
ScACS2 were amplified using respective primers listed in Supplementary Table S3. The PCR  372 product was assembled with SnaBI digested pYLXP' or pYLXP'2 using Gibson Assembly 373 method. YlARO1 is composed of 2 extrons and 1 intron. The extrons were amplified by using 374 primer pairs ARO1_up F/ARO1_up R and ARO1_down F/ARO1_down R respectively. The 375 resulting PCR products were assembled with SnaBI digested pYLXP' to yield pYLXP'-ARO1, 376 removing the intron sequence. For gene expression, the start codon was removed and a nucleic 377 acid sequence "TAACCGCAG" was added at the upstream of coding gene to complete the 378 intron 34 . 379
The YaliBrick method was used to assemble the synthetic pathways 34 . pYLXP' derived 380 plasmids were used to assemble the pathways of Module I, while pYLXP'2 derived plasmids 381 were used to assemble the pathways of Module II and ACS and ACC. Generally, the donor 382 plasmids were digested with AvrII/SalI, and the destination plasmids were digested with 383
NheI/SalI. The resulting plasmids containing monocistronic configurations were obtained by T4 384 ligation. For the assemble of genes containing any of these isocaudomers, other isocaudomers 385 were used. Specifically, the donor plasmid pYLXP'-YlARO1 was digested with HpaI/NheI, and 386 the destination plasmid pYLXP'-T4Sx5I was digested with HpaI/AvrII. The resulting plasmid 387 pYLXP'-AT4Sx5I was obtained by inserting YlARO1 into pYLXP'-T4Sx5I using T4 ligation. The 388 donor plasmid pYLXP'2-HRx2H was digested with ClaI/NheI, and the destination plasmid 389 pYLXP'2-ScACS2-YlACC1 was digested with ClaI/AvrII. The resulting plasmid 390 pYLXP'2-HRx2H-ScACS2-YlACC1 was obtained by inserting genes GhF3'H-CrCPRx2-SlF3H 391 into pYLXP'2-ScACS2-YlACC1 using T4 ligation. Plasmids pYLXP'2-YlACC1, 392 pYLXP'2-EcACCABCD-EcBirA, and pYLXP'2-YlBPL1 were frozen stocks of our laboratory 393 34 . Plasmids used in this paper were listed in Supplementary Table S4 . 394
Yeast transformation and screening 395
The lithium acetate (LiAc) method was used for the transformation. Y. lipolytica was 396 cultured on YPD plate at 30 o C for 16-22 h. The transformation solution was prepared as follows: 397 90 μL 50% PEG4000, 5 μL 2 M LiAc, 5 μL boiled single strand DNA (salmon sperm, 398 denatured), and 200-500 ng plasmid DNA. The transformation solution was mixed well by 399 vortexing before use. Next, the yeast was transferred to the transformation solution, and mixed 400 well by vortexing for at least 10 seconds. The transformation mixtures were then incubated at 401 30˚C for 30-45 min. The transformation mixture was then vortexed for 15 seconds every 10 402 minutes, followed by an additional 10 min heat shock at 39 o C to increase transformation 403 efficiency. For the transformation of pYLXP' and derivative plasmids, the mixture was plated on 404 leucine drop-out complete synthetic media (CSM-Leu). For the transformation of pYLXP'2 and 405 derivative plasmids, the mixture was plated on uracil drop-out complete synthetic media 406 (CSM-Ura). For the transformation of both plasmids, the mixture was plated on leucine and 407 uracil drop-out complete synthetic media (CSM-Leu-Ura). Strains NarPro/ASC, ErioPro, and 408
TaxiPro were constructed in previous work 40 . Strains used in this paper were listed in Strains 409 constructed in this project were listed in Supplementary Table S2 . 410
Cultivation and pH control 411
The seed was cultured in regular leucine, or uracil, or leucine and uracil drop-out complete 412 synthetic media (CSM-Leu, or CSM-Ura, or CSM-Leu-Ura) at 30 o C for 2 days. The seed culture 413 was inoculated to 25 mL nitrogen-limited media (C/N = 80) to a final concentration of 2% (v/v). 414
The fermentation was carried out in 250 mL shak flask at 30 o C 220 rpm. C/N ratio was 415 optimized by two patterns: i) fixing glucose content (40 g/L) and altering (NH4)2SO4 content; ii) 416 fixing (NH4)2SO4 content (0.73348 g/L) and altering glucose content. To analyze the effect of 417 cerulenin, oleic acid, and sodium acetate (NaAc) on flavonoid synthesis, a final concentration of 418 5 g/L oleic acid or 1 mM NaAc was added at the starting point, while a final concentration of 1 419 mg/L cerulenin was added at 48 h. To buffer the acidity, 20 mM phosphate buffer saline (PBS, 420 Na2HPO4-NaH2PO4) or 40 g/L CaCO3 was used respectively. In the fed-batch fermentation, the 421 starting glucose concentration was 40 g/L, and a final concentration of 10 g/L glucose was added 422 every 24 h from 48 h. 423
Analytical methods 424
Samples were taken at 144 h. In the fed-batch fermentation, samples were taken every 24 h. 425
For naringenin, eriodictyol, and taxifolin analysis, samples were diluted in methanol; whole for 426 glucose analysis, samples were diluted in H2O. Samples were shaken with glass beads to release 427 the metabolites for analysis. Naringenin, eriodictyol, taxifolin, and glucose were analyzed using 428
Agilent HPLC 1220 as previously described 40 
